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Nebulised surface-active hybrid 
nanoparticles of voriconazole for pulmonary 
Aspergillosis demonstrate clathrin-mediated 
cellular uptake, improved antifungal efficacy 
and lung retention
Ranjot Kaur1,2, Sarah R. Dennison2, Andrea J. Burrow2, Shivaprakash M. Rudramurthy3, Rajan Swami1, 
Varun Gorki4, O. P. Katare1, Anupama Kaushik5, Bhupinder Singh1,6* and Kamalinder K. Singh2,7,8* 
Abstract 
Background: Incidence of pulmonary aspergillosis is rising worldwide, owing to an increased population of immuno-
compromised patients. Notable potential of the pulmonary route has been witnessed in antifungal delivery due to distinct 
advantages of direct lung targeting and first-pass evasion. The current research reports biomimetic surface-active lipid-poly-
mer hybrid (LPH) nanoparticles (NPs) of voriconazole, employing lung-specific lipid, i.e., dipalmitoylphosphatidylcholine and 
natural biodegradable polymer, i.e., chitosan, to augment its pulmonary deposition and retention, following nebulization.
Results: The developed nanosystem exhibited a particle size in the range of 228–255 nm and drug entrapment of 
45–54.8%. Nebulized microdroplet characterization of NPs dispersion revealed a mean diameter of  ≤ 5 μm, corrobo-
rating its deep lung deposition potential as determined by next-generation impactor studies. Biophysical interaction 
of LPH NPs with lipid-monolayers indicated their surface-active potential and ease of intercalation into the pulmonary 
surfactant membrane at the air-lung interface. Cellular viability and uptake studies demonstrated their cytocompat-
ibility and time-and concentration-dependent uptake in lung-epithelial A549 and Calu-3 cells with clathrin-mediated 
internalization. Transepithelial electrical resistance experiments established their ability to penetrate tight airway 
Calu-3 monolayers. Antifungal studies on laboratory strains and clinical isolates depicted their superior efficacy 
against Aspergillus species. Pharmacokinetic studies revealed nearly 5-, 4- and threefolds enhancement in lung AUC, 
 Tmax, and MRT values, construing significant drug access and retention in lungs.
Conclusions: Nebulized LPH NPs were observed as a promising solution to provide effective and safe therapy for 
the management of pulmonary aspergillosis infection with improved patient compliance and avoidance of systemic 
side-effects. 
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Introduction
Pulmonary aspergillosis (PAP) has raised vital concerns 
in clinical healthcare, as it mainly affects people with 
weak immune systems. It is one of the major co-morbid 
infections in diseases like asthma, influenza, chronic 
obstructive pulmonary disease, tuberculosis, cancer, etc. 
[1, 2]. Recent reports on Covid-19 patients have also 
shown PAP as one of the major infections associated in 
almost 30–35% of the cases on mechanical ventilators, 
thus increasing their mortality rate by as much as 50% 
[3–6]. Primarily caused by the ubiquitous fungus, i.e., 
Aspergillus fumigatus, the leading risk factors associated 
with this opportunistic infection includes damaged res-
piratory epithelium, impaired mucociliary clearance and 
attenuated local immune system [7].
The currently available antifungal regimen is restricted 
to oral and parenteral routes only, which limits the thera-
peutic availability of drugs in the lungs owing to limitations 
of poor solubility, low permeability and rapid clearance of 
drug [8]. Pulmonary route offers myriad advantages like 
faster onset of action, localized non-invasive therapy, cir-
cumnavigation of the first-pass effect and reduced systemic 
side effects [9]. Concerted and immediate research efforts, 
therefore, are required to develop an effective pulmonary 
drug delivery system for the therapeutic management of 
PAP. In the absence of any of such commercially available 
product, the nebulized liposomal amphotericin B (AmB) 
has been administered as an inhalation for off-label use 
[10]. Also, in mechanically ventilated Covid 19 patients, 
nebulised liposomal AmB has been successfully given as a 
prophylactic therapy to avoid any potentially detrimental 
outcomes [3]. However, AmB usage needs to be restricted 
owing to its nephrotoxic nature [11]. Voriconazole, a first-
line antifungal triazole, is strongly recommended as the 
preferred antifungal triazoles in the therapeutic and pro-
phylactic management of PAP, as per the guidelines of the 
Society of Infectious Diseases Pharmacists [12, 13]. Vori-
conazole, administered through conventional routes, has 
demonstrated equivalent or superior efficacy to AmB with 
reduced side-effects in various clinical trials [14, 15]. Not 
much, however, is known regarding its pulmonary safety, 
efficacy and pharmacokinetics, upon nebulization. Exten-
sive investigations, therefore, are called for to ratify the 
effectiveness of voriconazole through nebulization in the 
potential treatment of PAP.
Recent advancements in the realm of nanotechnology 
have provided significant impetus to inhalation drug 
delivery. Drug nanocarriers tend to provide definitive 
benefits of superior biopharmaceutical properties, 
enhanced lung permeability, and improved dissolu-
tion profiles vis-à-vis the corresponding conventional 
therapy [16–19]. A therapeutic efficacy of the inhaled 
nanoparticles is highly dependent on their ability to 
overcome extrapulmonary and intracellular pulmonary 
barriers. Therefore, designing nanocarriers with an aim 
to minimize their premature mucociliary clearances 
and improving internalization at the air-lung interface 
through positive bio-interactions, has been gaining 
continued importance [16, 20]. This rationalizes the 
burgeoning interest in the application of bioinspired 
materials for fabricating nanoparticles for pulmonary 
delivery [21, 22].
Pulmonary surfactant being the first biological barrier 
of the respiratory surface, restricts the entry of foreign 
particles into lungs [23, 24]. Native pulmonary surfactant 
consists of various lipids (circa 90%) and surfactant pro-
teins (circa 10%). Amongst the lipids, dipalmitoylphos-
phatidylcholine (DPPC), a lung-specific phospholipid, 
constitutes as the major portion (circa 50–60%) of the 
lung surfactant [23]. Accordingly, we herein investigate 
nebulized DPPC coated chitosan (CH) nanoparticles 
(NPs) for the pulmonary delivery of voriconazole. CH, 
a natural polysaccharide, has shown immense potential 
and acceptance in the inhalational drug delivery due to 
its biodegradable, mucoadhesive, permeation-enhancing 
and controlled release characteristics [25–27]. The pres-
ence of DPPC coating on NPs surface enhance its bio-
compatibility as well as increase its interaction with the 
pulmonary surfactant monolayers (PSM), which line 
the inner epithelial surface of lung alveoli at the air–liq-
uid interface [21, 23]. Moreover, it minimizes the mac-
rophage uptake, thereby facilitating NPs diffusion and 
internalization into the lung epithelial cells. These sur-
face-active lipid-polymer hybrid (LPH) nanosystems, 
with distinctive advantages of the polymeric as well as 
the lipidic systems, has shown promise for delivering 
voriconazole to the lungs. The present work encompasses 
development of LPH NPs, following the systematic prin-
ciples of Quality by design (QbD), and subsequent exten-
sive characterization and evaluation, including aerosol 
characterization (Scheme  1). Besides, the present stud-
ies also examined the air-lung lipid membrane interac-
tion via Langmuir–Blodgett trough and cellular transport 
pathways of NPs, using fluorescence microscopy and 
flow cytometric analysis. Furthermore, the antifungal 
efficacy of NPs was assessed in laboratory strains as well 
Keywords: Pulmonary aspergillosis, Voriconazole, Inhalation, Antifungal, Hybrid nanoparticles, Phospholipid, 
Chitosan, Cell uptake, Lung retention
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as clinical respiratory isolates of the Aspergillus species. 
Comprehensive in  vivo studies to determine the lung 
and plasma pharmacokinetics, and to establish the safety 
of the formulation unearthed the immense potential of 
these hybrid systems, in the domain of pulmonary drug 
delivery of antifungals.
Materials and methods
Voriconazole and DPPC were gifted by M/s Life Care 
Laboratories Ltd., India, and by M/s Lipoid, Germany, 
respectively. Medium-molecular weight CH and Rho-
damine 123 (Rh-123) were purchased from M/s Sigma 
Aldrich, UK, while sodium tripolyphosphate (TPP) and 
Tween 80 (T80) were procured from M/s Acros Organ-
ics and M/s Fisher Scientific, India, respectively. All 
other chemicals, reagents, and solvents employed during 
the current research work were of analytical grade and 
were used as acquired. Adenocarcinoma human alveolar 
basal epithelial (A549) cells and human bronchial epithe-
lial (Calu 3) cells were purchased and maintained as per 
M/s ATCC, Manassas, USA.
Synthesis of chitosan nanoparticles (CH NPs)
CH NPs were prepared by ionic gelation method [28]. 
Briefly, CH was added to 1% (v/v) acetic acid solution and 
stirred for overnight on a magnetic stirrer at 500  rpm. 
An anionic cross-linker (i.e., TPP in the ratio of 1: 2.5 
v/v) was added to CH solution containing T80. Similarly, 
the drug- or dye-loaded NPs were prepared by dissolving 
20 mg of voriconazole, or 10 µg/mL of Rh-123, in 2 mL of 
ethanol and then adding to the CH-surfactant solution, 
before drop-wise addition of a suitable cross-linker.
Factor screening and optimization as per design 
of experiments (DoE)
Factor screening studies were conducted employing a 
seven-variable eight-run Taguchi design to identify the 
highly influential product and process variables affect-
ing CH NPs (Additional file  1: Table  S1). Half-normal 
and Pareto plots were used for quantitative analysis of 
the influence of all the individual product and process 
variables on each of the selected critical quality attrib-
utes (CQAs) [29]. A Box-Behnken design (BBD) with 
17 experimental runs (Additional file  1: Table  S2) was 
employed for optimization of CH NPs using Design 
 Expert® software version 11.0 (M/s Stat-Ease, USA) [29, 
30].
Preparation of lipid‑polymer hybrid nanoparticles (LPH 
NPs)
LPH NPs were prepared by the electrostatic interac-
tion method [31]. Briefly, different ratios of CH NPs 
dispersion and ethanolic solution of DPPC (2 mL) were 
incubated for 20  min at 4  °C and subjected to high 
energy sonication employing a probe sonicator (M/s 
Vibra Cell Sonics, USA) for 5  min at 30% amplitude 
for coating a lipid layer on the CH NPs. The optimized 
LPH NPs were subsequently lyophilized, employing a 
suitable combination of cryoprotectants.
Characterization studies
The particle size (PS), zeta potential (ZP), and polydisper-
sity index (PDI) of the NPs were analyzed using dynamic 
laser scattering (DLS) equipment (Nano ZS, M/s Mal-
vern, UK), set at a temperature of 25 °C. The nanoparticle 
dispersion was diluted 50-folds with purified water, prior 
to each such measurement.
Entrapment efficiency (EE) was determined by both 
indirect and direct methods. LPH NPs (1  mL) were 
taken and centrifuged at 20,000g for 2 h at 10  °C. For 
indirect method, supernatant was removed and was 
analyzed for free VRC content, employing a previously 
validated high-performance liquid chromatography 
(HPLC) method on a chromatograph (M/s Waters, 
USA) with acetonitrile and acetic acid solution (50:50) 
as mobile phase, at flow rate of 1  mL.minute−1 [32, 
33]. Further, the direct method involved the wash-
ing of pellet, thrice with water, and then dissolving it 
in 2% acetic acid solution and methanol, followed by 
probe sonication for 15  min and filtration through 
0.4-micron syringe filter. Subsequently, VRC con-
tent was analyzed using previously validated HPLC 
method. The surface morphology of voriconazole and 
NPs were investigated employing a Field Emission 
Scanning Electron Microscope (FESEM, Su8010, M/s 
Hitachi, Japan). Further, the drug-excipient compat-
ibility studies were carried out by KBr pellet method 
using a Fourier Transformed Infra-Red (FTIR) spec-
trometer (M/s Perkin Elmer, USA). Spectra for VRC, 
CH, TPP and DPPC, along with their physical mixture 
 (Pmix) and LPH NPs, were recorded and studied for 
any noticeable shift(s) in the peaks. Crystallographic 
structure of the pure drug, physical mixture, and LPH 
NPs were recorded on a powder X-ray diffractometer 
(M/s PAN analytical, Netherlands). The samples were 
packed in sample holder  and scanned between 5 and 
50° in 2θ [34].
In vitro drug release studies
Drug release studies were performed employing the 
dialysis sac technique [35]. The NPs dispersion (contain-
ing VRC equivalent to 1.4  mg) or voriconazole suspen-
sion were placed in a dialysis sac (12  kDa, M/s Sigma 
Aldrich, UK), tethered at both the ends and suspended 
at 37 ± 0.5  °C at 100  rpm in 20  mL of phosphate buffer 
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saline (PBS 7.4) and 0.1% of Tween 80 (v/v) to maintain 
the desired sink conditions. Samples were periodically 
withdrawn and assayed for voriconazole content using 
HPLC. Drug release profiles of LPH NPs were plotted 
and underlying drug release kinetic behaviour was ascer-
tained [36].
Microdroplet laser diffraction analysis
Spraytec laser diffraction equipment (M/s Malvern 
Panalytical, Malvern, UK) was employed to acquire the 
volume droplet size distribution of the nebulized aerosol-
cloud [37]. The instrument was equipped with He–Ne 
laser to acquire the volume-droplet size distribution of 
an aerosol cloud instantaneously, with an acquisition fre-
quency of 10 kHz. [38]. Four types of nebulizers, three of 
Scheme 1 Preparation of dipalmitoyl phosphatidylcholine (DPPC) coated chitosan hybrid nanoparticles by electrostatic interaction method. 
The nanoparticle dispersion was nebulised as microdroplets for effective targeting the respiratory airways by the mechanism of diffusion. Once 
deposited, their cellular uptake inside the lung epithelial cells is a determinant of their particle size and surface charge
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these the jet nebulizers, viz, Omron C803 (Omron), Pari 
LC (Pari), and Sidestream (Respironics), and one mesh 
nebulizer viz, Aeroneb (Aerogen), were used to generate 
microdroplets of LPH NPs dispersion. The experiment 
was performed in triplicate, and the parameters, such as 
Dx (10), Dx (50), and Dx (90), were calculated employing 
Spraytec version 3.20 software. The nebulizer delivering 
the dispersions with best volume mean diameter (VMD) 
was selected for further particle deposition studies.
Next‑generation impactor (NGI) studies
Particle deposition studies of LPH NPs dispersion were per-
formed employing an NGI at a flow rate of 15 L.  minute−1. 
Sidestream nebulizer was attached to the induction port 
of an NGI (M/s Copley Scientific, UK) using a mouthpiece 
adapter and filled with 10 mL of LPH NPs dispersion with 
an aerosol collection time of 5  min [39]. After complet-
ing the measurement, the cup holder tray was taken out, 
and each stage of the impactor was washed with 10 mL of 
extraction solvent (methanol and 1% acetic acid solution), 
filtered and subjected to HPLC analysis for determining the 
voriconazole content. Mass median aerodynamic diameter 
(MMAD) and geometric standard deviation (GSD) were 
computed employing online MMAD calculation software 
[40]. Other parameters, like fine particle fraction (FPF) and 
emitted dose (ED), were also calculated as per the standard 
formulas [41].
Influence of nebulization on the particle size of LPH NPs
Nebulizers generate extensive shear forces on the parti-
cles getting aerosolized, which could alter their integrity 
during the process. In order to ensure that the integrity 
and stability of NPs is maintained during nebulization, 
the PS of the LPH NPs was examined, before and 20 min 
after nebulization using DLS [42].
Surface activity using langmuir troughs
Surface activity determination of drug and LPH NPs
Surface activity of native voriconazole solution (1 × PBS 
pH 7.4) and drug loaded LPH NPs was investigated 
using a 15 cm2 Teflon Langmuir trough (M/s Biolin Sci-
entific, UK). Samples were injected into 10 mM, pH 7.4 
PBS using a Hamilton microsyringe to yield the final 
drug concentrations ranging between 0 and 100  µM. 
Surface pressure changes were monitored by the While-
mly plate (Whatman’s CH1 filter paper) attached with 
a microbalance [43] and were plotted against drug 
concentrations.
Interaction of LPH NPs with model cell membrane 
monolayers
Potential interaction of LPH NPs and voriconazole 
solution (1 × PBS 7.4) at the air-lung lipid membrane 
interface was investigated using lung cell monolayer 
mimics of either DPPC or cellular lipids extracted from 
A549 cells as described in Additional file section [44]. 
Biophysical interaction of LPH NPs and voriconazole 
solution with lipid monolayer was studied at a constant 
pressure using 80 mL of 601 M Teflon trough with mov-
able barriers. Chloroform solution of the lipids (0.5 mM) 
was spread onto a buffer subphase (1x PBS pH 7.4), and 
the solvent was allowed to evaporate (30 min). The mon-
olayer was compressed at a velocity of 10 cm2  min−1 to 
gain a surface pressure of 30 m N  m−1, which is mimetic 
of naturally occurring membranes [45]. Using barrier 
control, the lipid monolayer was maintained at this area 
throughout the experiment. After the equilibration of 
monolayer for 10  min, the samples were injected sepa-
rately into subphase to yield the final concentration of 
50 μM. Augmentation in the surface pressure was moni-
tored using NIMA software and was subsequently plot-
ted against time [43].
Antifungal efficacy
The antifungal susceptibility of voriconazole, blank and 
drug loaded LPH NPs was carried out by the micro 
broth dilution method using Roswell Park Memorial 
Institute 1640 as growth medium. The laboratory strains 
as well as the clinical isolates of Aspergillus viz., Asper-
gillus fumigatus, Aspergillus flavus (obtained from bron-
choalveolar lavage), were exposed to LPH NPs at the 
drug concentrations varying between 0.029 and 14.84 µg 
 mL−1. Besides, Candida krusie and Candida parapsilosis 
strains were also exposed to LPH NPs. The incubation 
for Aspergillus and Candida species was carried out at 
35  °C in a dark and humid chamber for a period of 24 
and 48  h, respectively. The values of MIC were deter-
mined employing a visual endpoint, as per the recom-
mendations of the Clinical and Laboraotry Standard 
Institute (CLSI) [46].
In vitro cell line studies
Safety studies
The cell viability profile of voriconazole, blank and drug-
loaded LPH NPs was investigated on A549 (5 × 103 cells/
cm2) and Calu 3 cells (1 × 104 cells/cm2) in a 96-well plate 
(M/s Thermo Fischer Scientific, Denmark) via the Presto 
blue assay. Cells were seeded using a standard protocol, 
and the culture medium was replenished with 90 µL of 
the medium containing LPH NPs.
(0.31 to 40 µg  mL−1) and incubated for a period of 48 h. 
 PrestoBlueTM (M/s Invitrogen, USA) 10 µL, was added to 
each of the well and incubated for a period of 1 h, follow-
ing which the fluorescence was recorded using a micro-
plate reader (M/s Tecan, Männedorf, Switzerland), at the 
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excitation and emission wavelengths of 535 and 612 nm, 
respectively [30].
Qualitative cellular internalization study
A549 (1×105 cells/well) and Calu 3 (2×105 cells/
well) were seeded on coverslips in 6 well-plates (M/s 
Thermo Scientific, Denmark), and transferred to a 
humidified incubator. When the cells reached 85–90% 
confluency, the plates were taken out of the incuba-
tor, washed with PBS (0.1 M, pH 7.4, 1 mL) twice and 
subsequently incubated for a period of 4 h with 10 μg 
 mL−1 of Rh-123 loaded-LPH NPs (Rh-LPH NPs). Fol-
lowing incubation, the treated cells were washed using 
PBS thrice and analysed under a fluorescence micro-
scope (M/s Carl Zeiss, UK) with an oil lens at 63x 
magnification [30].
Quantitative cellular uptake studies
The cellular uptake studies were conducted to evaluate 
the effect of concentration and time on the uptake of Rh-
LPHNPs in A549 (5×104 cells/well) and Calu 3 (1x  105 
cells/well) cells using a flow cytometer  (Guava® easy-
Cyte HT, M/s Merck, Germany). Varied concentrations 
of formulation (i.e., 1, 2.5, 5 μg  mL−1) were incubated at 
37 ± 1  °C in pre-cultured lung epithelial cells in 12 well-
plates for varying time intervals, i.e., 0.5, 1, 2, 4 and 6 h, 
and estimated for mean fluorescence intensity [47].
Mechanistic endocytosis pathway analysis
A549 (5×104 cells/well) and Calu 3 (1×105cells/well) 
were seeded in 12 well-plates. Upon 80–90% confluency, 
the cells were exposed to different endocytosis inhibitors 
for 90  min before treating with Rh-LPH NPs. Sucrose 
(0.45 M), nystatin (5 μg  mL−1), and cytochalasin B (5 μg 
 mL−1) were employed to block the clathrin-mediated, 
caveolae/lipid rafts and macropinocytosis pathways, 
respectively. After 90 min, the medium containing endo-
cytic inhibitors was removed and replaced with 1  μg 
 mL−1 of Rh-LPH NPs, diluted with medium-plus endo-
cytic inhibitors, followed by incubation for 4 h at 37 °C. 
The effect of energy-dependent endocytosis was also 
observed by placing the cells at 4 °C. Samples were pro-
cessed, as per the standard protocol, and subjected to 
flow cytometer [47].
Permeability assay
An aliquot of 400 μL of Calu-3 cell suspension 
(5×105 cells/cm2) was seeded on the apical side of the 
 Transwells® (0.4  mm pore size, 12  mm diameter), and 
1 mL of complete medium was added to the basolateral 
side to allow the monolayer to grow at the liquid-liquid 
interface (LLI). The transepithelial electrical resistance 
(TEER) of the Calu-3 monolayers was monitored at the 
pre-determined day intervals using a volt-ohm meter 
(Millicell ERS-2, M/s Merck, Darmstadt, Germany) and 
the inserts showing TEER value less than 1000-ohm 
 cm−2 were excluded from the study. Moreover, the cell 
monolayer integrity was also challenged by the applica-
tion of highly permeable azo dye, i.e., Evans blue (10 μg 
 mL−1). After confirming the monolayer integrity, the 
medium from the apical side was replaced with Rh-
LPH NPs (1  μg  mL−1). Aliquots of samples (100 μL 
each) were withdrawn from the basolateral side after 
the periodic time intervals of 0.5, 1, 2, 4, and 6 h, and 
subsequently replaced each time with fresh transport 
medium [48]. The samples were analyzed using a fluo-
rescence microplate reader (GENios  Pro®, M/s Tecan 
UK Ltd., Theale, UK) to monitor the concentration of 
the Rh-LPH NPs, while setting the excitation wave-
length at 535 and emission wavelength at 612  nm. A 
plot between the cumulative amount of Rh-LPH NPs 
permeated and time was constructed and apparent per-
meability (Papp) was computed using Eq. 1 [30].
where, A is the surface area of membrane (1.12 cm2),  C0 
is the initial Rh-LPH NPs concentration on apical side 
(1 µg  mL−1) and dQ/dt is the steady state flux.
Lung and plasma pharmacokinetic studies
In vivo studies were carried out on Balb/c mice (23 ± 2 g) 
as per ethical approval from the Institutional Animal 
Ethics Committee of the Panjab University (PU/45/99/
CPSEA/IAEC/2019/243). The mice were kept in the 
open polycarbonate cages associated with wire-lid hold-
ing chow-and-water bottles, in a well-ventilated room at 
a temperature of 25 ± 2 °C and humidity of 65–70%. Ani-
mals were fed with standard pellet diet and water ad libi-
tum. The mice were acclimatized for a period of 14 days 
prior to animal experimentation. A total of 48 animals 
used for the study were divided into two groups in a ran-
domized manner. All the animals were fasted for over-
night prior to experimentation [49]. Group I received 
LPH NPs inhalation, while Group II received inhalation 
of a commercially available intravenous formulation of 
voriconazole (Vorier, M/s Zydus Cadila, India), at a dose 
of 15 mg with the flow rate of 1.40 ± 0.13 L  min−1 [50]. 
The time period of 20 min was chosen for nebulization in 
line with usual time opted in clinical practice [51]. Mice 
(n = 3 each) were euthanized by cardiac puncture at spec-
ified time intervals of 0.2, 0.5, 1.0, 2.0, 4.0, 8.0, 12.0 and 
24.0  h [52]. Whole blood samples were collected in the 
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and the resultant plasma samples were stored at −20 °C, 
till further analysed. Further, lungs were excised and 
stored at −20 °C till quantitatively analysed for voricona-
zole content employing HPLC [32]. Different pharma-
cokinetic parameters, like maximum lung and plasma 
concentrations (i.e.,  Cmax) and the corresponding time 
points to reach  Cmax (i.e.,  Tmax), area under the curve (i.e., 
AUC), and mean residence time (i.e., MRT), were com-
puted employing PK solver spreadsheet software [53].
In vivo safety studies
The safety studies for LPH NPs were conducted in 
Balb/c mice on four of the animal groups. Group I was 
designated as naïve group, while Groups II, III, and IV 
received nebulization of normal saline (NS 0.9%), vori-
conazole (15 mg), and LPH NPs (equivalent to 15 mg of 
voriconazole), respectively, at a flow rate of 1.40 ± 0.13 L 
 min−1. Treatments were administered regularly twice-a-
day for 20 min, consecutively for a period of 21 days. The 
animals were sacrificed at the end of 21  days-period by 
cardiac puncture [50], and various tissue specimens were 
examined for any noticeable morphological changes.
Stability studies
The stability of the lyophilized voriconazole LPH 
NPs was determined employing humidity cham-
bers (M/s Newtronic Lifecare Equipment, Mumbai, 
India). The samples were stored in glass vials for a 
period of 90  days at different temperature and humid-
ity conditions, i.e., 5 °C ± 3 °C, 25 °C ± 2 °C/60 ± 5% RH; 
40  °C ± 2  °C/75 ± 5% RH [54]. The lyophilized samples 
were reconstituted in sterile water at 0, 30 and 90 days, 
bath-sonicated for 30 min, and were analysed for possible 
change in PS, PDI and EE.
Statistical data analysis
Statistical analysis was conducted by one-way analysis of 
variance (ANOVA), and an unpaired t test was used for 
individual comparisons employing Prism Software (M/s 
GraphPad Inc., La Jolla, USA).
Results
DoE‑based screening and optimization studies
Considered as a vital prioritization exercise as a prelude 
to optimization studies, factor screening assumes factor 
additivity and absence of any interaction(s), thus calling 
for employment of an apt linear model (Eq. 2). Analysis 
of consequent half-normal and Pareto plots unravel that 
CH, TPP, and T80 form as highly influential CMAs for 
CH NPs formulation, as is apparent from their statisti-
cally significant (p < 0.05–0.001) effects, much above the 
critical t-value and Bonferroni lines (Additional file  1: 
Figure S1). Other factors, such as pH (4.0), stirring speed 
(800  rpm), stirring time (60  min), and probe sonication 
time (3 min), were accordingly kept as constant. 
where y is the response variable, β0 represents the inter-
cept form, and β1 to β7 depict the coefficients of the cor-
responding linear model terms.
The response surface optimization graphs tend to facil-
itate explicit comprehension of the studied factors, along 
with their possible interactions, of each of the investi-
gated CQAs of the CH NPs. The 3D-and 2D response 
surface plots were constructed for each of the CQAs, 
viz. PS, PDI, ZP, EE, and DL (Additional file  1: Fig. S2 
(a-o). The magnitudes of coefficients of the second-order 
polynomial equation are provided in Additional file  1: 
Table S3. Additional file 1: Figure S3 illustrates the over-
lay plot, with design space marked in yellow colour and 
values of the CQAs obtained for the optimized formula-
tion of CH NPs, comprising of CH (2.1 mg  mL−1), TPP 
(1.9 mg  mL−1) and T80 (3.6 mg  mL−1) [29].
Characterization studies
Varying the proportions of polymer, cross-linker, and 
surfactant contributed to the formation of either clear, 
opalescent or turbid solutions, with a mean PS ranging 
between 83.5 and 781.3 nm, ZP between 8.3 and 25.1 mV 
and EE between 26.3 and 48.2%. The desired region of CH 
NPs was obtained in the opalescent zone, where the poly-
mer as well as cross-linker, was optimally used to form an 
ionic complex. Overall, the optimized CH NPs dispersion 
showed a PS of 174.00 ± 14.41  nm, PDI of 0.36 ± 0.05, 
ZP of 17.70 ± 0.42  mV, EE of 40.23 ± 4.76% (indirect 
method) and 35.03 ± 6.52% (direct method), and DL of 
5.42 ± 1.01%. Coating the CH NPs with DPPC resulted in 
spherical shaped LPH NPs with a smooth surface, as is 
evident from their FESEM images (Fig. 1 a-d). This was 
in sheer contrast to the rough surface demonstrated by 
the corresponding images of CH NPs. Presence of lipidic 
layer on to the surface of LPH NPs was found to increase 
the PS and decrease the ZP (Additional file 1: Table S4) 
[55, 56]. Presence of lipid coat augmented the drug EE 
by 1.3-folds, ostensibly owing to the presence of the 
adsorbed drug on the surface of LPH NPs. The physico-
chemical characteristics of the optimized LPH NPs were 
found to be significantly different from the uncoated CH 
NPs with a mean size of 240.2 ± 12.10  nm (p < 0.005), 
ZP of 9.42 ± 0.33 mV (p < 0.001) and EE of 54.80 ± 5.19% 
(p < 0.05), as analysed using the indirect method. How-
ever, the difference in PDI (i.e.,0.28 ± 0.03), EE (i.e., 
45.46 ± 3.89) by direct method, DL (i.e.,6.28 ± 0.40%) 
was observed to be statistically insignificant (p > 0.05) 
for LPH NPs. A blend of mannitol (5%) and Trehalose 
(2)
y = β0 + β1X1 + β2X2 + β3X3 + β4X4
+ β5X5 + β6X6 + β7X7
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(5%) was found to be more conducive for lyophilization 
of LPH NPs than either of them when used alone (Addi-
tional file  1: Table  S5). The lyophilized LPH NPs exhib-
ited a PS of 268.9 ± 15.16 nm, PDI of 0.30 ± 0.017, ZP of 
8.25 ± 1.17 mV and EE of 52.86 ± 2.54%.
The FTIR spectrum (Additional file 1: Fig. S4) of vori-
conazole depicted peaks of C-N, C-F, and C–C stretching 
bands at 1099.80–1352.59, 1133.14–1408.38 and 1497.90 
-1589.87  cm−1, respectively [57, 58]. The spectrum of 
CH showed peaks at 3399.90  cm−1 for O–H, 2856.30–
3399.90 cm−1 for C-H stretching, and 1075.27 cm−1 for 
C-O stretching bands. Principal bands present in the 
DPPC spectrum included O–H stretching at 3038.68–
3304.77  cm−1, C-H stretching at 2851.03–2954.40-
28  cm−1, ester carbonyl groups at 1740.24  cm−1 and 
 PO2− groups at 1090.23–1231.45  cm−1 [59]. The cor-
responding spectrum of the physical mixture showed 
the sum of vibrational frequencies of all the individual 
components. The FTIR spectrum of LPH NPs primarily 
depicted the characteristic peaks due to the lipid and pol-
ymer. The peaks corresponding to drug molecule per se 
were not evident, thus rationally indicating the successful 
encapsulation of voriconazole. Figure 1(e–h) display the 
X-RD pattern of pure voriconazole, demonstrating sharp 
characteristic peaks at 13.8°, 16.5, and 19.8°, while such 
sharp peaks were almost absent in LPH NPs, indicating 
predominately the amorphous nature of drug embedded 
in the NPs [34].
In vitro drug release studies
The drug release profile (Fig.  2) portrays that 
94.94 ± 2.50% of voriconazole got released from 
voriconazole suspension in 4 h. The developed LPH NPs 
show extended drug release for 48  h (70.29 ± 1.77%), 
with an initial burst release for 2 h (42.33 ± 3.93%). The 
drug release profile was found to be best fitted with the 
Korsmeyer-Peppas model (R = 0.927), with the value of 
diffusional release exponent (n) being 0.202 (< 0.45), indi-
cating the drug release to be primarily governed by Fick-
ian mechanism (Additional file 1: Table S6).
Microdroplet size analysis by spraytec
Four nebulizers were investigated for their suitability to 
form appropriate inhalable microdroplets of LPH NPs 
dispersion. Other than Aeroneb Solo mesh nebulizer, 
which displayed Dx (50) of 14.24 µm, all other jet nebu-
lizers exhibited Dx (50) of less than 5 µm (Fig. 3a). This 
could be ascribable to the blockage of the mesh of the 
Aeroneb Solo nebulizer by any free polymeric fibres that 
may be generated in the nanoparticulate dispersion dur-
ing nebulization, resulting eventually in the generation of 
uneven droplet size(s). Other parameters like GSD, Span, 
percentage of the volume of particles less than 5 µm, etc., 
were also analysed for the spray pattern, as enumerated 
in Table 1. Based upon the results of Dx (50) µm, GSD, 
and   % volume of particles less than 5  µm, Sidestream 
nebulizer was found to be optimum for the nebuliza-
tion of LPH NPs and was finally selected for evaluating 
the pulmonary deposition during the current studies. 
Further, the aerodynamic parameters obtained after the 
nebulization of normal saline solution employing Side-
stream nebulizer were found to be insignificant (p > 0.05), 
when compared with LPH NPs nebulization, as depicted 
vividly in Fig. 3b.
Fig. 1 FESEM images of a Voriconazole at 6 K, b Chitosan nanoparticles at 60X (inset laser diffraction histogram), c Lipid-polymer hybrid 
nanoparticles at 60X (inset laser diffraction histogram) and d lipid-polymer hybrid nanoparticles at 120X; PXRD spectra of e Voriconazole, f physical 
mixture of drug and excipients, g Chitosan nanoparticles and h lipid-polymer hybrid nanoparticles
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Particle deposition studies by NGI
The in vitro pulmonary deposition data of LPH NPs are 
presented as percentage of total drug deposited in the 
device, throat and various stages of NGI, with reference 
to the total mass recovered (Fig. 3c), revealing maximum 
drug deposition at Stage 4 (cut-off of 3.3 μm) and Stage 
3 (cut-off of 5.4  μm) of the impactor, respectively. The 
MMAD and GSD were found to be 4.12 μm and 2.25 μm, 
respectively, with 86% of the dose emitted from the nebu-
lizer, and an FPF as 55.5%.
Effect of particle size on nebulization of LPH NPs
The effect of shear forces of nebulizer on PS of LPH 
NPs is illustrated in Fig. 4. A marginal (258.2 ± 15.5 nm; 
p > 0.05) augmentation in the PS was observed following 
20 min of nebulization (Table 2), thereby demonstrating 
the stability of the developed nanosystem during the pro-
cess of nebulization.
Surface activity experiments
As portrayed in Fig. 5a, the surface pressure at air/water 
subphase tends to increase initially with increased drug 
concentration until saturation was achieved. For LPH 
NPs, the bulk concentration of 50  µM was observed to 
be the minimum requirement for saturating the air/water 
interphase, indicating that the voriconazole NPs were 
more surface-active than native voriconazole (p < 0.05). 
Furthermore, at the minimum bulk concentration, LPH 
NPs were observed to be highly surface-active displaying 
surface pressure increase of 19.75 ± 1.28 mN  m−1, which 
is a characteristic of the membrane interactive com-
pound [60].
Interactions of drug and nanoparticles with lipidic 
monolayers
Native voriconazole displayed minimal surface activ-
ity with a change in pressure (Δπ) of less than 1 mN 
 m−1 (Fig.  5b), thereby indicating nominal interaction 
with the phospholipid headgroups. On the other hand, 
LPH NPs illustrated Δπ of more than 3 mN  m−1, indi-
cating expeditious ingress and intercalation of the NPs 
into the erstwhile hydrophobic acyl chain region of the 
monolayer [61]. This surface pressure increase followed 
hyperbolic kinetics and showed maximal values that 
ranged between 36.9 and 38.0 mN  m−1, when studied 
for a time period of 2000s, consistent with membrane 
interactions of the acyl chain region [62].
Analogous to the aforesaid findings obtained with 
DPPC monolayers, the LPH NPs showed a rapid 
increase in surface pressure (Δπ of 4 to 5 mN  m1) 
upon interaction with the A549 lipid monolayer, thus 
revealing their fusogenic properties (Fig.  5c). A lower 
level of interaction, however, was observed for such 
monolayers, wherein voriconazole induced a modest 
Fig. 2  Cumulative drug release profile of voriconazole (VRC) and its optimised Lipid-polymer hybrid nanoparticles (LPH NPs) in PBS 7.4, for a period 
of 48 h. Data is expressed as mean ± SD (n = 3)
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surface pressure alteration i.e., 1 mN  m−1. The ini-
tial interaction of LPH NPs with both the monolay-
ers for a period of 400 s was different from each other. 
A slower increase in surface pressure was observed 
with DPPC monolayers, while a rapid rise followed by 
stagnant phase was observed with A549 lipid monolay-
ers (Fig. 5d).
Antifungal studies
The MIC values for LPH NPs were observed to be much 
lower in magnitude for the studied laboratory strains, 
Fig. 3 a Microdroplet characterization of lipid-polymer hybrid nanoparticles of voriconazole by Spraytec laser diffraction employing air-jet and 
mesh nebulizers at a distance of 3 cm from laser beam for 60 s, b microdroplet comparison of normal saline solution versus lipid-polymer hybrid 
nanoparticles using Sidestream nebulizer, and c next-generation impactor deposition pattern of lipid-polymer hybrid nanoparticles on various 
stages of impactor at a flow rate of 15 L.  minute−1. Data is expressed as mean ± SD (n = 3)
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while equal in magnitude to voriconazole in the clinical 
isolates of Aspergillus species, and lower in magnitude 
for Candida species (Table 3).
In vitro cell lines study
Safety studies
Safety and compatibility of the formulation with the 
lung cells play a crucial role in developing a pulmonary 
drug delivery system, since the inhalation of any toxic 
substances may lead to depletion of lung surfactant and 
recruitment of phagocytic cells [9]. Both blank and drug-
loaded LPH NPs did not compromise the cell viabil-
ity, as more than 80% of cells were found to be viable as 
compared to control (p > 0.05), on being treated with the 
highest (40 µg  mL−1) drug concentration (Fig. 6a, b).
Qualitative and quantitative uptake studies
Fluorescent images of A549 and Calu 3 cells incubated 
for 4  h with Rh-LPH NPs reveal the presence of con-
siderable green fluorescence inside the cells confirm-
ing the co-localization of Rh-LPH NPs in the airway 
cells, where blue colour represents the staining of the 
nucleus with DAPI, as portrayed in Fig. 7(a–d). It is evi-
dent that the cellular uptake of Rh-LPH NPs was both 
time-(Fig. 7e, f ) and concentration-dependent (Fig. 7g). 
The internalization of NPs increases quite linearly 
with time, though they tend to plateau at higher levels 
beyond 4 h of treatment. Nearly 1.3-folds increase in 
the internalization was observed in Calu 3 cells vis-à-
vis A549 cells at higher concentrations, for a period of 
4 to 6 h.
Mechanistic pathway
Endocytosis enables cells to internalize nutrients, includ-
ing macromolecules and NPs. Temperature-dependent 
uptake studies revealed that the energy-dependent active 
endocytic process was responsible for the uptake of Rh-
LPH NPs in both the cell lines, as the internalization of 
NPs was reduced by five to sixfolds (p < 0.0001) w.r.t. 
control. NPs internalize in the cells by various mecha-
nisms, and the preferred route of entry may depend 
Fig. 3 continued
Table 1 Comparison of  performance characteristics 
of different nebulizers
Dv(10): Microdrolpets below which 10% spray lies, Dv(50): Microdrolpets below 
which 50% spray lies, Dv(90): Microdrolpets below which 90% spray lies, GSD 
Geometric standard deviation; $: nebulizer finally selected for performance 






Dv(10) µm 5.89 ± 0.88 1.82 ± 0.07 1.89 ± 0.06 1.90 ± 0.04
Dv(50) µm 14.23 ± 1.21 4.37 ± 0.14 4.44 ± 0.19 4.20 ± 0.10
Dv(90) µm 31.31 ± 0.60 10.17 ± 0.39 10.03 ± 0.63 8.76 ± 0.17
GSD 1.91 ± 0.15 1.89 ± 0.06 1.83 ± 0.02 1.73 ± 0.04
Span 1.77 ± 0.18 1.95 ± 0.04 1.83 ± 0.05 1.63 ± 0.01
%V < 5 µm 7.17 ± 4.22 58.92 ± 1.75 56.85 ± 2.60 61.08 ± 1.40
%V < 1-3 µm 1.55 ± 1.07 30.40 ± 1.73 28.60 ± 1.69 29.67 ± 1.24
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on the properties of the carrier and the cell type [63]. 
Internalization of LPH NPs in A549 cells was primarily 
attributed to the clathrin-mediated pathway (i.e., sucrose 
inhibition), as the uptake of NPs was reduced by 3.2-folds 
w.r.t. control (p < 0.0001), and significant effect was also 
observed with cytochalasin B (p < 0.001), a macropino-
cytosis pathway-specific inhibitor. In Calu-3 cells, how-
ever, two transport pathways were majorly involved, i.e., 
clathrin-mediated and macropinocytosis as internaliza-
tion was reduced by 3.9-and 2.1-folds (p < 0.0001 each), 
respectively in the presence of sucrose and cytochalasin 
B, the specific inhibitors for each of these pathways. Nev-
ertheless, the insignificant effect was observed on inter-
nalization (p > 0.05) with nystatin on both the cell lines, 
thus ruling out the involvement of caveolae-dependent 
pathway for uptake (Fig. 8a and Additional file 1: Fig. S5).
Permeability studies
Reduction in TEER of Calu 3 monolayer, after exposure 
to NPs, w.r.t control (Additional file 1: Fig. S6) could be 
attributed to the slight opening of the tight junctions 
connoting paracellular transport, though the resistance 
remained well above the 1000  ohm  cm−2 verifying that 
the integrity of the monolayer was intact [64]. The integ-
rity of the monolayer was further confirmed by no evi-
dent leakage of Evans blue when challenged at the end of 
treatment. Percent permeation of LPH NPs, as illustrated 
in Fig.  8b, unequivocally construes the potential of the 
formulation to transport across Calu-3 cell layers, in con-
sonance with our cellular uptake studies with the Papp of 
Rh-LPH NPs as 5.79 ± 0.86 × 10−6 cm  s−1.
Plasma and lung pharmacokinetic studies
The mean lung concentration–time profiles of voricona-
zole solution (Fig. 9a) show a rapid decline of drug levels 
following nebulization vis-à-vis that obtained with LPH 
NPs, thus leading to a distinct change in varied phar-
macokinetic parameters (Table 4). As much as 4.9-folds 
(p < 0.0005), 5.7-folds (p < 0.0001), 3.1-folds (p < 0.005), 
3.9-folds (p < 0.01), and 2.0-folds (p < 0.05) augmentation 
in the values of AUC 0-24, AUC 0-∞, MRT,  Tmax and  Cmax 
was observed, respectively, with LPH NPs w.r.t. pure 
voriconazole.
On the other hand, plasma level time profile of voricon-
azole following nebulization (Fig. 9b), the mean values of 
 Tmax were observed to be 1.67  h for LPH NPs vis-à-vis 
0.39 h (4.3-folds, p < 0.01) for the marketed formulation. 
The AUC 0-24 (2.0-folds), AUC 0-∞ (2.4-folds), MRT (2.1-
folds) were also found to be significantly higher (p < 0.05 
each) for the LPH NPs w.r.t. the marketed brand. The 
magnitude of  Cmax, however, was not found to be signifi-
cantly different (1.1-folds, p > 0.05).
Fig. 4 Effect of shear forces of Sidestream nebulizer on particle size of voriconazole lipid-polymer hybrid nanoparticles (LPH NPs) before and after 
nebulization of 20 min
Table 2 Effect of nebulization on particle size of LPH NPs
ns non-significant
Parameter Particle size P‑value
Before nebulization 229.4 ± 14.2 –
After 10 min of nebulization 242.7 ± 20.5 0.388 (ns)
After 20 min of nebulization 258.2 ± 15.5 0.076 (ns)
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In vivo safety studies
Histopathological descriptions of sections of various 
Balb/c mice tissue specimens, viz. lungs, liver, spleen, and 
kidney, upon repeated nebulization of LPH NPs twice 
daily for a period of 21  days, showed only insignificant 
changes vis-à-vis the corresponding naïve group (Fig. 10). 
Mild distortion, however, was observed in the mice lungs 
treated with voriconazole and LPH NPs of voricona-
zole. However, no significant pathological changes, i.e., 
ulceration of the airways or oedema, was observed, in 
Fig. 5 a Surface activity of voriconazole (VRC, blue) and lipid-polymer hybrid nanoparticles (LPH NPs, orange) at air/water subphase. Different 
compound concentrations (0–100 µM) were introduced into the subphase (10 mM PBS buffer, pH 7.4) of a Langmuir–Blodgett system, b DPPC 
monolayer interaction with VRC and LPH NPs for 2000s, c A549 cell lipid monolayer interaction with VRC and LPH NPs for 2000s and d change in 
surface pressure experienced with introduction of VRC and LPH NPs into lipid monolayers for initial 400 s
Table 3 Values of minimum inhibitory concentration (MIC) of voriconazole (VRC) and lipid polymer hybrid nanoparticles 
against different fungal strains
LPH NPs lipid polymer hybrid nanoparticles, R Respiratory clinical isolate
Type of strain Fungal strain Labortory I.D. MIC (µg.  mL−1)
VRC Blank LPH NPs Drug loaded 
LPH NPs
Laboratory strains Candida krusei CK 6258 0.23 14.84 0.11
Candida parapsilosis CP 22,019 0.05 14.84 0.03
Aspergillus flavus ATCC 204304 0.92 14.84 0.46
Aspergillus fumigatus ATCC 204305 0.92 14.84 0.23
Clinical isolates Aspergillus flavus R 4443 0.92 14.84 0.92
Aspergillus fumigatus R 4322 0.92 14.84 0.92
Aspergillus fumigatus R 4784 0.92 14.84 0.92
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concurrence with the results reported by Tolman et  al. 
[50]. The liver of the treated groups exhibited no signs 
of distortion as parenchymal cells, and the central vein 
was distinct. Similarly, the architecture of spleen in all 
the groups was quite normal, with an intact trabecula 
and capsule. No signs, whatsoever, of the medullary cyst 
or nephropathy, were noticeable in the test population, 
though a mild increase in the space of glomerulus capsule 
was observed for LPH NPs vis-à-vis control.
Fig. 6 Cell viability assay of voriconazole (VRC) and lipid-polymer hybrid nanoparticles (LPH NPs) on a A549 cells and b Calu 3 cells for 48 h 
employing Presto Blue assay. Data is expressed as mean ± SD (n = 3)
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Stability studies
Table  5 demonstrates the stability data of LPH NPs at 
different storage conditions. LPH NPs were found to be 
stable at 5 °C for a period 90 days vis-à-vis at higher tem-
peratures. No notable changes were observed at 25 °C for 
Fig. 7 Fluorescence microscopic images of cellular uptake of Rhodamine 123 loaded lipid-polymer hybrid nanoparticles (10 µg.mL−1of R 123) 
depicted by Green fluorescence, Blue fluorescence-nuclei stained with DAPI, a A549 control cells, b A549 treated cells, c Calu 3 control cells, and 
d Calu 3 treated cells. Time-dependent uptake studies in e A549 3 cells and f Calu 3 cells. g Concentration-dependent uptake studies in A549 and 
Calu 3 cells. Data is expressed as mean ± SD (n = 3)
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30 days, while significant increase in PS and reduction in 
EE were observed after 90 days.
Discussion
With the growing incidences of aspergillus lung infec-
tions, the ardent need of the hour today is to make effi-
cacious therapeutic strategies available for its prevention 
and eradication, demonstrating efficient targeting to the 
infected cells vis-à-vis invasive parenteral drug delivery 
approaches. Development of safe, effective, biocompati-
ble localized pulmonary therapy is, accordingly, called for 
to address this impending vital issue. Concerted as well 
as collaborative endeavours have, therefore, been under-
taken in the current studies to develop LPH NPs of a 
standard antifungal drug, voriconazole, in order to attain 
its efficient localized therapy.
The standard protocol of electrostatic interaction was 
opted to prepare LPH NPs. The solubility of CH in 1% 
acetic acid solution was obtained ostensibly due to pro-
tonation of an amine group of CH into ammonium ions, 
as acetic acid in solution gets converted to acetate ions 
 (CH3COO−) and  (H+) ions [65]. The positive charge on 
the CH NPs was predicted to attract negatively charged 
acetate ions that shield the cationic centres from interact-
ing with the negatively charged lipids. The ammonium 
 (NH4+) groups present in the zwitterionic DPPC may 
divert the negatively charged acetate ions from the acetic 
acid solution, thus enabling more frequent interactions 
between the anionic phosphate groups of DPPC and the 
cationic surface of CH NPs. Moreover, the high-energy 
input by sonication seemed to facilitate the lipid organi-
zation around the CH NPs surface. Presence of DPPC 
coating was confirmed by an increment in the PS and 
diminution in the ZP [55, 65]. Further, the FESEM images 
distinctly revealed perceptible changes in the morphol-
ogy between CH NPs and LPH NPs, rationally assign-
able to the contribution of the lipid layer in providing a 
smooth surface and spherical shape to the latter com-
pared to the relatively rough surface and irregular shape 
of the former. Difference in the values of EE of LPH NPs 
between the indirect and direct methods can ostensibly 
be ascribed to adsorption of some amount of drug onto 
the surface of the NPs. The presence of any sharp crys-
talline peak(s) of voriconazole was almost absent in the 
XRD patterns of LPH NPs, which principally ratify the 
amorphous character of the prepared NPs.
PBS was employed as the dissolution medium owing to 
its simple composition, better buffering effect and apt-
ness for demonstrating sustained release characteristics 
or pH-dependent profile [66]. Further, the pH of PBS was 
fixed at 7.4 to reflect the pH of lung lining fluid [67]. LPH 
NPs portrayed a typical biphasic drug release profile in 
PBS 7.4, with an early short period burst release, followed 
by a relatively long controlled release phase for a period 
of 48 h. This initial burst release could be attributed to a 
sizeable amount of the drug adsorbed onto the surface of 
LPH NPs [68]. The subsequent controlled release could 
Fig. 7 continued
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be ascribed to the contribution of CH in these lipid-poly-
mer hybrid nanoconstructs.
The primary goal of drug delivery via inhalation is to 
achieve the desired drug levels in the lungs. Globule size 
is one of the major factors known to influence particle 
deposition in the lungs. NPs, owing to their smaller size, 
have demonstrated low deposition efficiency. Therefore, 
LPH NPs were nebulized employing a jet nebulizer for 
the generation of NPs-embedded into microdroplets 
with MMAD and VMD ranging between 1 and 5  µm, 
Fig. 8 a Mechanistic pathways: Effect of endocytic inhibitor on cellular uptake of Rh123 labelled lipid-polymer hybrid nanoparticles in A549 and 
Calu 3 cells, b percent permeation of Rh 123 labelled lipid-polymer hybrid nanoparticles in Calu 3 monolayers for a period of 6 h. Data is expressed 
as mean ± SD (n = 3). ns nonsignificant, **P < 0.001, ***P < 0.0001
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as particles > 5  µm are documented to get deposited in 
the large conducting airways as well as in oropharyn-
geal region [69]. MMAD (4.12 µm) of LPH NPs disper-
sion as determined using NGI, delineates that the aerosol 
possesses the ability to reach smaller airways, alveoli, 
and deposits primarily through the mechanism of sedi-
mentation and diffusion in the airways. Furthermore, 
VMD (4.20  µm) calculated from Spraytec (p > 0.05) 
corroborates well with the results obtained using NGI. 
The variability in dispersity of aerosol droplets was pre-
dicted by GSD, where GSD value of 1 tends to construe 
a monodisperse aerosol, while it indicates a hetero-
disperse aerosol for a GSD value > 1.2 [69]. The results 
obtained with the current studies showed hetero disper-
sity of the generated aerosol cloud in concurrence with 
previous findings [69, 70]. The size and integrity of NPs, 
Fig. 9  Pharmacokinetic profiles of voriconazole (VRC) and lipid-polymer hybrid nanoparticles (LPH NPs) at different time-points in (a) Lungs and 
(b) Plasma, following nebulization for 20 min to Balb/c mice through inhouse nose-only inhalation chamber. Data expressed in mean ± SD, n = 3 
mice/group. The corresponding inset depicts percent change in different pharmacokinetic parameters
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Table 4 Pharmacokinetic parameters following  nebulization of  voriconazole (VRC) and  its  lipid-polymer  hybrid 
nanoparticles (LPH NPs)
Data expressed as mean ± SD (n = 3)
Parameter(s) Lung pharmacokinetics Plasma pharmacokinetics
VRC solution VRC LPH NPs VRC solution VRC LPH NPs
Cmax (μg mL
−1) 13.43 ± 3.10 26.29 ± 5.78 6.81 ± 1.11 7.79 ± 2.07
Tmax(h) 0.17 ± 0.00 0.67 ± 0.29 0.39 ± 0.19 1.67 ± 0.38
AUC 0-24 (μg mL
−1*h) 36.38 ± 5.40 177.75 ± 23.40 33.89 ± 5.05 69.01 ± 10.25
AUC 0-∞ (μg mL
−1*h) 41.77 ± 6.75 237.51 ± 22.98 35.94 ± 6.11 89.16 ± 16.71
MRT (h) 5.27 ± 1.31 16.46 ± 2.87 7.13 ± 1.03 15.26 ± 3.44
Fig. 10 Photomicrographs showing histopathological changes in various organs of Balb/c mice after receiving twice daily nebulisation of a control, 
no treatment, b normal saline, c VRC and d LPH NP dispersion for a period of 21 days. AS alveolar sac, CV central vein, H hepatic vein, G glomerulus, 
M medullary vein, T trabecula, W white pulp, R red pulp, C capsule
Table 5 Stability study data for freeze-dried hybrid nanoparticles of voriconazole
PS Particle size, PDI polydispersity index, EE Entrapment efficiency
Parameters Zero day After 30 days After 90 days
5 ± 3 °C 25 ± 2 °C/60 ± 5% 
RH
40 ± 2 °C/75 ± 5% 
RH
5 ± 3 °C 25 ± 2 °C/60 ± 5% 
RH
40 ± 2 °C/75 ± 5% 
RH
PS (nm) 270.2 ± 17.3 273.2 ± 21.14 278.6 ± 33.02 405.9 ± 31.75 282.8 ± 30.11 478.3 ± 40.85 531.5 ± 37.89
PDI 0.312 ± 0.012 0.373 ± 0.018 0.389 ± 0.047 0.431 ± 0.194 0.349 ± 0.024 0.580 ± 0.104 0.871 ± 0.117
EE (%) 52.25 ± 2.72 51.72 ± 2.81 49.34 ± 3.01 43.92 ± 3.57 50.43 ± 3.91 44.84 ± 3.48 36.67 ± 4.59
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nevertheless, were quite well-maintained within the 
nebulized droplets, without any perceptible aggregation 
[71].
Langmuir–Blodgett air–liquid interphase monolayer 
models are widely accepted for investigating the interac-
tion of cellular lipids with therapeutic moieties, as they 
mimic the naturally occurring membrane interfaces [45, 
62]. The present studies, in this regard, demonstrated 
the distinct surface-active potential of LPH NPs vis-
à-vis pure drug attributed to the DPPC coating on the 
CH NPs. Indeed, the membrane interactive potential 
of LPH NPs could help explain the kinetics of insertion 
into monolayers of DPPC and lung surfactant mimicking 
endogenous membrane comprising of A549 lipid extract 
(Fig. 5). The insertion of LPH NPs into the DPPC mon-
olayers took 500  s to achieve maximal surface pressure 
(Fig. 5b), whereas only 50 s (Fig. 5c) for intercalation into 
A549 lipid monolayers. These data clearly suggest that 
LPH NPs not only enhances the interaction into DPPC 
and A549 monolayers but also facilitates rate of inser-
tion into these membranes, indicating that the NPs has 
enhanced safety and stability, which can be accredited to 
the DPPC coating on the NPs.
In vitro compatibility studies revealed the safety of the 
LPH NPs in bronchoalveolar epithelial cells at the high-
est concentration tested. The qualitative data illustrated 
the co-localization of the developed nanosystems and 
exhibited their accumulation in the cytoplasm of lung 
epithelial cells, while the quantitative analysis revealed 
that the internalization of LPH NPs increased with time 
and dose. Interestingly, this augmentation appeared to be 
steeper at higher concentration of NPs with Calu 3 cells, 
displaying higher internalization than observed with 
A549 cells. As the positively charged NPs are known to 
internalize by clathrin-mediated endocytosis (CME), this 
pathway was considered primarily responsible for the 
internalization of the positively charged LPH NPs in the 
current studies, for A549 as well as Calu-3 cells. Electro-
static interactions seemed to be primarily involved in the 
receptor-independent CME [47, 72, 73]. As NPs usually 
employ multiple pathways to internalize, macropinocyto-
sis, postulated to be involved in the uptake of both posi-
tively and negatively charged NPs, was also construed as 
one of the likely internalisation pathways of LPH NPs in 
Calu 3 cells [74]. For studying NPs translocation, Calu-3 
cells are the most relevant respiratory cell culture model, 
because of their ability to form tight monolayers vis-à-vis 
A549 cells [75]. In the current study, the high magnitude 
of Papp, i.e., > 5 × 10−6 cm  s−1 for LPH NPs across Calu 
3 monolayers, connotes the distinctive potential of the 
nanosystems to open tight junctions and transport across 
a monolayer of the cells [76].
The in vitro antimicrobial data on fungal isolates unrav-
elled the potential of developed nanosystems to target 
the most prominent strain of fungal lung infections viz., 
Aspergillus fumigates responsible for causing more than 
60% of the lung infections [8], followed by other Asper-
gillus and Candida species.
Currently, no inhalational formulation of voriconazole 
being commercially available, intravenous injection  was 
nebulized to compare the lung deposition and plasma 
concentration profile of LPH NPs in mice. A previous 
report on the inhaled voriconazole injection has shown 
improved survival in the murine model of Aspergillus 
fumigatus infection [77]. Loading voriconazole into LPH 
NPs evidently revealed high lung retention vis-à-vis the 
marketed voriconazole solution. A notable improvement 
in the values of  Cmax and  Tmax, reveal significant enhance-
ment in the intensity and duration of voriconazole expo-
sure to lungs on nebulisation of LPH NPs. This could be 
hypothesized to the ability of LHP NPs to circumvent all 
the three pulmonary barriers, i.e., physical, biochemi-
cal and cellular [23]. In the current studies, as the NPs 
exhibited size less than 0.5  μm, they were apparently 
capable of overcoming the physical barrier and settle in 
the lungs by the mechanism of Brownian diffusion [78]. 
Further, modification of CH NPs with pulmonary sur-
factant lipid, viz, DPPC, could be postulated to impede 
the adhesion of NPs with mucus biochemical barrier and 
escape deposition in the upper airways [79]. Once the 
NPs reach the alveolar spaces, the DPPC coating facili-
tates their interfacial spreading at the air lung interface 
[80]. This is followed by intercalation into the PSM where 
they are exposed to highly dynamic environment and 
resist lung clearance owing to their surface-active char-
acteristics [81, 82]. Integration of NPs with PSM pro-
motes their interaction with alveolar epithelial cells and 
enhances their internalization through cellular pathways, 
thereby improving the AUC values and residence time of 
voriconazole in the lungs [23]. Native voriconazole with 
marginal surface activity is prone to removal during the 
constant compression and expansion of PSM during 
breathing, which could be the plausible reason for its fast 
clearance with no detectable levels of the drug in the lung 
tissue after 12 h [83].
The enhanced values of  Tmax in the plasma are ascrib-
able to the slower diffusion of LPH NPs from the lungs, 
thereby allowing enough time for the cellular uptake of 
these nano-contoured systems within the lungs. The 
enhanced AUC values in plasma could plausibly be 
assigned to the presence of large alveolar surface area and 
thin physiological membrane in the lungs, which tend to 
promote drug diffusion into the systemic circulation [84, 
85]. The results, therefore, signify the immense potential 
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of LPH NPs for the management of invasive fungal 
disorders.
Safety of the developed formulation is vital for its 
potential clinical application(s). The toxicity studies 
revealed insignificant changes with no obvious organ 
damage either to the lungs or to the other vital organs, 
including heart, kidneys, liver, and spleen, following 
repeated-dose administration for 21 days. This corrobo-
rates the safety and biocompatibility of the LPH NPs 
upon nebulization to mice, which could be judiciously 
attributed to the usage of lung endogenous phospholipid, 
which has shown high potential to mimic the normal 
lung surfactant.
Lyophilization was shown to enhance the stability 
of colloidal NPs. LPH NPs, lyophilized with 5% man-
nitol and 5% trehalose, get easily dispersed in water, 
upon reconstitution. The presence of trehalose as cryo-
protectant is known to enhance the stability of the NPs 
during freeze drying [86]. This could be postulated due 
to the physical isolation of adjacent NPs in the pres-
ence of glassy cryoprotectant to reduce the destabilising 
stress caused during the freezing process [87]. Significant 
changes (p < 0.05) in particle size were noted in LPH NPs 
stored at 40 °C, which could be rationally hypothesized to 
the aggregation of LPH NPs at higher temperatures [88]. 
Reduction in EE at 40 °C, could be attributed to the leak-
age of VRC from the NPs exposed to high temperature 
for prolonged period of time [86]. Accordingly, refrigera-
tion conditions of 5 ± 3  °C would be conducive for stor-
ing LPH NPs for a 90-day period.
Conclusions
Inhalation of antifungals has been emerging as an essen-
tial and effective therapy for the therapeutic management 
of fungal lung infections. Voriconazole-a first-line triazole 
usually gets rapidly cleared into the systemic circulation 
with low lung retention profiles, following nebulization. 
The current investigation, therefore, presents a novel 
inhalational delivery system comprising of lung-specific 
phospholipid coated CH NPs to augment the deposition 
and retention of voriconazole in the lungs. Various char-
acterization studies revealed robust nanostructured char-
acteristics of the prepared system with a modulated drug 
release profile and surface-active properties. In vitro pul-
monary deposition, studies ratify the distinct potential of 
the nebulized NPs to target the lungs, primarily through 
the mechanisms of sedimentation and diffusion. Biophys-
ical interaction of LPH NPs with lipid-monolayers con-
firm their surface-active potential and intercalation into 
the pulmonary surfactant barrier at the air-lung interface. 
In vitro cellular viability and in vivo histopathology stud-
ies construed safety potential and biocompatibility of the 
prepared lipid polymer nanocarrier system. The phar-
macokinetic studies delineated enhanced lung retention 
with improved biopharmaceutical attributes. In  vitro 
efficacy in laboratory and clinical isolates of Aspergillus 
species prove their potential in treatment and prophy-
laxis of PAP as secondary infection in many respiratory 
conditions. Further research will be focused on evaluat-
ing the dose-dependent pharmacodynamic response of 
LPH NPs in the validated animal models. The knowledge 
and know-how gathered from the current research work 
would enable future researchers working in the realm of 
inhalational drug delivery to develop the next-generation 
smart aerosol systems with demonstrable evidence to 
improve lung targeting.
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